Steatohepatitis/Metabolic Liver Disease News

In this exclusive video, Nancy S. Reau, MD, section chief of hepatology and associate director of organ transplantation at Rush University Medical Center, discusses the lasting impacts of COVID-19 on hepatology practice.

The American Gastroenterological Association released guidance on consultative management of COVID-19 among patients with gastrointestinal and liver manifestations.

Voluntary liver stiffness screening via onsite ultrasound during the Minnesota State Fair yielded high prevalence of liver disease among people previously unaware of any liver disease while 1 month follow-up showed a 70% change of lifestyle in those presenting at high risk, according to data out of Digestive Disease Week.

First responders and those who worked at the site of the September 11 attacks on the World Trade Centers in New York City showed a prevalence of fatty liver at a four times greater occurrence than the general population, according to an expert presenting data during a press conference in advance of Digestive Diseases Week data publication.

The link between two metal ion transporters and MRI based corrected Tl demonstrated a new mechanism in steatohepatitis, according to a recently published article.

Biopsy-confirmed fibrosis was associated with risk for mortality and liver-related morbidity in patients with NAFLD, regardless of confounding factors and in patients with NASH, according to study results.

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.

The risk of fibrosis is highest in young adults with harmful drinking patterns and steatosis, according to data from a population-based study.

Axcella released an update from the ongoing clinical study of two potential therapies for nonalcoholic fatty liver disease that showed the compounds were safe, well-tolerated, and demonstrated relevant clinical response, according to a press release.

NASHNET has designated the Central Virginia VA Health Care System as its eighth founding charter member and “center of excellence” in recognition of the system’s work in fatty liver disease, according to a press release.